Document is current

Article History

Received: 4 March 2025

Accepted: 21 August 2025

First Online: 12 September 2025

Declarations

:

: They reported to have received fees as follows: N.D.: Advisory Boards and speakers bureaus AstraZeneca, Aurikamed, BGGF, Daiichi-Sankyo, Elsevier Verlag, ESO, Exact Sciences, Gilead Sciences, GSK, if-Kongress, KelCon, Leopoldina Schweinfurt, Lilly, Lukon, Molekular Health, MSD, Novartis, onkowissen, Pfizer, RG-Ärztefortbildungen, Roche, Seagen. K.-H.K.: Advisory Boards and speakers bureaus AstraZeneca, MSD, BMS, Merck, Roche, Sanofi-Aventis, Icotec, Varian, Carl Zeiss Meditec AG and ELEKTA. M.B.-P.: Fees for lectures and consulting activities: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Medical, Syantra, resitu, Pierre Fabre, ExactSciences; Study support: EndoMag, Mammotome, MeritMedical, Sirius Medical, Gilead, Hologic, ExactSciences, Claudia von Schilling Stiftung, Damp Stiftung, Ehmann Stiftung Savognin; Coverage of travel and congress costs: Eli Lilly, ExactSciences, Pierre Fabre, Pfizer, Daiichi Sankyo, Roche, Stemline. C.D.: Roche, AstraZeneca, TEVA, Mentor, and MCI Healthcare. R.F.: Elsevier Verlag. C.M.W.: Novartis, BGGF, if-Kongrss, RG Gesellschaft für Information und Organisation. M.B.K.: speaker honorars from Eisai GmbH, AstraZeneca, Aurikamed, Novartis, coverage of travel and congress costs: MSD Sharp&Dohme GmbH, Lilly GmbH, the other authors have no competing interests.

: The protocol was approved by the Ethics Committee of Ludwig-Maximilian-University (Munich) (approval 20-0953; 04.03.2021). Informed consent was given by all subjects involved in the study.